## Recast as a de-risked “reverse-merger + cornerstone financing” (not a typical tuck-in) The latest 8‑K makes clear this is effectively a pipeline-and-capital reset: Sensei acquired Faeth via a two-step merger structure and issued **Series B non-voting convertible preferred** to Faeth holders as consideration. ["acquired Faeth"](0001193125-26-056135|0) ["issued… Series B"](0001193125-26-056135|0) On a fully diluted, as‑converted basis **post-financing**, legacy Sensei holders are projected to own **~4.9%**, while Faeth holders and the new PIPE investors collectively own **~95.1%**—a tell that the “asset” being bought is really *the new company*. ["will hold approximately 4.9%"](0001193125-26-056135|0) ## The $200M PIPE is not just cash—it’s institutional underwriting of the thesis The disclosure frames the private placement as **~$200 million** gross proceeds tied to **Series B non-voting convertible preferred stock**, with named participation from multiple specialist funds. ["gross proceeds… $200 million"](0001193125-26-056135|7) ["Series B… private placement"](0001193125-26-056135|7) Mechanically, the PIPE is sized at **14,440.395 shares of Series B** for **~$200 million**, with an expected close date of **February 20, 2026** (customary conditions). ["sell… 14,440.395 shares"](0001193125-26-056135|0) ["expected to occur on February 20, 2026"](0001193125-26-056135|0) Hidden-in-plain-sight “alpha” here: management is explicitly linking proceeds to near-term, value-defining readouts—i.e., investors are underwriting a catalyst calendar, not a long, indefinite platform build. ["use the proceeds primarily"](0001193125-26-056135|7) ## Catalyst stacking through YE2026: multiple shots on goal, not a single binary Per the company’s own use-of-proceeds language, capital is primarily allocated to advance **PIKTOR** toward (1) **topline Phase 2 data** in **second-line advanced endometrial cancer** and (2) initiating a **Phase 1b** in **HR+/HER2‑ advanced breast cancer**, both expected **by year-end 2026**, while also completing Sensei’s ongoing **Phase 1/2 solnerstotug** trial. ["topline data… Phase 2"](0001193125-26-056135|7) ["initiation of a Phase 1b"](0001193125-26-056135|7) ["both expected by year end 2026"](0001193125-26-056135|7) ["completion… Phase 1/2 trial"](0001193125-26-056135|7) ## The real near-term “gating item”: stockholder approval drives automatic conversion (and control) Series B is structured to **automatically convert into 1,000 common shares per preferred share** *after* stockholder approval of the specified matters, with beneficial ownership blockers that can range (by holder election) between **4.99% and 19.99%**. ["automatically convert into 1,000 shares"](0001193125-26-056135|0) ["between 4.99% and 19.99%"](0001193125-26-056135|0) The 8‑K also discloses Sensei is committing to a stockholder meeting to vote on (among other items) the conversion approval, a “change of control” approval, and an authorization increase up to **300,000,000** common shares (and potentially a reverse split). ["agreed to hold a stockholders’ meeting"](0001193125-26-056135|0) ["increase of up to 300,000,000 shares"](0001193125-26-056135|0) ["reverse stock split"](0001193125-26-056135|0) Read-between-the-lines takeaway: the market focus may be on the press release, but the *process alpha* is around how quickly the company can clear these approvals to remove structural overhang and fully normalize the capital structure. ["Conversion Proposal"](0001193125-26-056135|0) ["Change in Control Proposal"](0001193125-26-056135|0) ## Supply/overhang management is being engineered (registration + lockups), not left to chance The filing discloses a defined path to liquidity: the company plans to file a resale registration statement (Form S‑3 if eligible) within **75 days** following the financing close to register resale of shares issued/underlying the deal securities. ["within 75 days"](0001193125-26-056135|0) At the same time, certain insiders and pre-merger holders entered **180‑day lock-ups**, which can dampen immediate supply pressure as the new story is introduced. ["180-day lockup"](0001193125-26-056135|0) If you want, I can also extract and synthesize the **investor presentation (Ex. 99.2)** for additional “between-the-lines” signals (e.g., what endpoints they emphasize, implied differentiation, and how they message tolerability vs efficacy). ["Investor Presentation"](0001193125-26-056135|0)

## Recast as a de-risked “reverse-merger + cornerstone financing” (not a typical tuck-in) The latest 8‑K makes clear this is effectively a pipeline-and-capital reset: Sensei acquired Faeth via a two-step merger structure and issued **Series B non-voting convertible preferred** to Faeth holders as consideration. ["acquired Faeth"](0001193125-26-056135|0) ["issued… Series B"](0001193125-26-056135|0) On a fully diluted, as‑converted basis **post-financing**, legacy Sensei holders are projected to own **~4.9%**, while Faeth holders and the new PIPE investors collectively own **~95.1%**—a tell that the “asset” being bought is really *the new company*. ["will hold approximately 4.9%"](0001193125-26-056135|0) ## The $200M PIPE is not just cash—it’s institutional underwriting of the thesis The disclosure frames the private placement as **~$200 million** gross proceeds tied to **Series B non-voting convertible preferred stock**, with named participation from multiple specialist funds. ["gross proceeds… $200 million"](0001193125-26-056135|7) ["Series B… private placement"](0001193125-26-056135|7) Mechanically, the PIPE is sized at **14,440.395 shares of Series B** for **~$200 million**, with an expected close date of **February 20, 2026** (customary conditions). ["sell… 14,440.395 shares"](0001193125-26-056135|0) ["expected to occur on February 20, 2026"](0001193125-26-056135|0) Hidden-in-plain-sight “alpha” here: management is explicitly linking proceeds to near-term, value-defining readouts—i.e., investors are underwriting a catalyst calendar, not a long, indefinite platform build. ["use the proceeds primarily"](0001193125-26-056135|7) ## Catalyst stacking through YE2026: multiple shots on goal, not a single binary Per the company’s own use-of-proceeds language, capital is primarily allocated to advance **PIKTOR** toward (1) **topline Phase 2 data** in **second-line advanced endometrial cancer** and (2) initiating a **Phase 1b** in **HR+/HER2‑ advanced breast cancer**, both expected **by year-end 2026**, while also completing Sensei’s ongoing **Phase 1/2 solnerstotug** trial. ["topline data… Phase 2"](0001193125-26-056135|7) ["initiation of a Phase 1b"](0001193125-26-056135|7) ["both expected by year end 2026"](0001193125-26-056135|7) ["completion… Phase 1/2 trial"](0001193125-26-056135|7) ## The real near-term “gating item”: stockholder approval drives automatic conversion (and control) Series B is structured to **automatically convert into 1,000 common shares per preferred share** *after* stockholder approval of the specified matters, with beneficial ownership blockers that can range (by holder election) between **4.99% and 19.99%**. ["automatically convert into 1,000 shares"](0001193125-26-056135|0) ["between 4.99% and 19.99%"](0001193125-26-056135|0) The 8‑K also discloses Sensei is committing to a stockholder meeting to vote on (among other items) the conversion approval, a “change of control” approval, and an authorization increase up to **300,000,000** common shares (and potentially a reverse split). ["agreed to hold a stockholders’ meeting"](0001193125-26-056135|0) ["increase of up to 300,000,000 shares"](0001193125-26-056135|0) ["reverse stock split"](0001193125-26-056135|0) Read-between-the-lines takeaway: the market focus may be on the press release, but the *process alpha* is around how quickly the company can clear these approvals to remove structural overhang and fully normalize the capital structure. ["Conversion Proposal"](0001193125-26-056135|0) ["Change in Control Proposal"](0001193125-26-056135|0) ## Supply/overhang management is being engineered (registration + lockups), not left to chance The filing discloses a defined path to liquidity: the company plans to file a resale registration statement (Form S‑3 if eligible) within **75 days** following the financing close to register resale of shares issued/underlying the deal securities. ["within 75 days"](0001193125-26-056135|0) At the same time, certain insiders and pre-merger holders entered **180‑day lock-ups**, which can dampen immediate supply pressure as the new story is introduced. ["180-day lockup"](0001193125-26-056135|0) If you want, I can also extract and synthesize the **investor presentation (Ex. 99.2)** for additional “between-the-lines” signals (e.g., what endpoints they emphasize, implied differentiation, and how they message tolerability vs efficacy). ["Investor Presentation"](0001193125-26-056135|0)